法国银屑病关节炎真实世界流行病学研究:基于医保数据库的队列分析
最常见合并症为高血压、糖尿病、慢性阻塞性肺疾病和血脂异常。最常用的治疗药物为b/bsDMARDs(30.4%)、csDMARDs(25.9%)和阿普米司特(3.5%)。
要点
- 法国成人PsA患病率0.1%,发病率8.4/10万人年。
- 常见合并症包括高血压、糖尿病、COPD和血脂异常。
- 最常用治疗为b/bsDMARDs(30.4%),其次csDMARDs(25.9%)。
核心结论
- 法国PsA患病率为0.1%,发病率为8.4/10万人年,结果与其他数据源研究相似,支持医保数据库用于此类研究的可靠性。
主要发现
- 共识别63 598例PsA患者,平均年龄55.9岁(s.d. 14.4),男性占45.6%。
- 最常见合并症为高血压、糖尿病、慢性阻塞性肺疾病和血脂异常。
- csDMARDs、b/bsDMARDs和阿普米司特的患病率分别为25.9%(16 453例)、30.4%(19 325例)和3.5%(2 231例)。
- 新使用csDMARDs者8 966例(14.1%),新使用b/bsDMARDs者8 311例(13.1%),新使用阿普米司特者1 529例(7.4%)。
- 一线csDMARD最常用为甲氨蝶呤(70.9%),一线b/bsDMARD最常用为阿达木单抗(30.8%)。
关键数值与推荐
- PsA患病率0.1%,发病率8.4/10万人年。
- csDMARDs、b/bsDMARDs、阿普米司特患病率分别为25.9%、30.4%、3.5%。
- 一线csDMARD中甲氨蝶呤占70.9%,一线b/bsDMARD中阿达木单抗占30.8%。
临床怎么用
- 真实世界数据显示PsA患者中合并症负担常见,应重视高血压、糖尿病、COPD和血脂异常的筛查与管理。
- b/bsDMARDs使用比例较高,甲氨蝶呤和阿达木单抗分别是常用的一线csDMARD和b/bsDMARD。
局限性
- 仅基于行政数据库ICD-10编码M07识别PsA,可能存在编码误差或漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PsA is a chronic inflammatory arthritis with heterogeneous disease manifestations. Data on the prevalence of PsA in adults differ widely depending on the study and the country. This study aimed to estimate the prevalence and incidence of PsA in France, characterize comorbidities associated to PsA and identify prescribed treatments. METHODS: This nationwide cohort study involved the administrative healthcare database (Système National des Données de Santé) of the French health insurance scheme linked to the national hospital discharge database. All adults with PsA registered in the database and identified with a specific International Classification of Diseases, 10th revision code (M07) were included between 1 January 2015 and 31 December 2018. RESULTS: A total of 63 598 patients were identified as having PsA [55.9 years (s.d. 14.4), 45.6% males]. The prevalence of PsA was estimated at 0.1% and the incidence at 8.4 per 100 000 person-years in the general population. The most common comorbidities were hypertension, diabetes, chronic obstructive pulmonary disease and dyslipidaemia. The prevalence of treatment with conventional synthetic DMARDs (csDMARDs), biological or biosimilar DMARDs (b/bsDMARDs) and apremilast for PsA was 25.9% (16 453), 30.4% (19 325) and 3.5% (2231), respectively. Overall, 8966 (14.1%) patients were new users of csDMARDs, 8311 (13.1%) were new users of b/bsDMARDs and 1529 (7.4%) were new users of apremilast. The most common first-line csDMARD was methotrexate (70.9%) and the most frequent first-line b/bsDMARD was adalimumab (30.8%). CONCLUSION: Our results lead to a better understanding of PsA. Results were similar to those from other published studies using other data sources, which highlights the reliability of insurance databases for studies.
引用
- Pina Vegas L, Sbidian E, Penso L, et al. Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database. Rheumatology (Oxford). 2021. PMID: 32911531. doi:10.1093/rheumatology/keaa448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。